SCA
IHE icon

Strategic Capital Alternatives’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Strategic Capital Alternatives’s Portfolio IHE Stock Details IHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,113
Closed -$52K – 207
2014
Q3 		$52K Buy
+1,113
New +$50.2K 0.02% 230

Other funds holding IHE

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
AWA
ARS Wealth Advisors St. Petersburg, Florida $556M AUM 30.03% 1-Year Est. Return
BCM
Brookstone Capital Management Wheaton, Illinois $9.99B AUM 23.61% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
BWM
Braver Wealth Management Needham, Massachusetts $616M AUM 12.48% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Strategic Capital Alternatives's IHE Position: Q4 2014 in Review

Strategic Capital Alternatives sold out of iShares US Pharmaceuticals ETF (IHE) in Q4 2014, closing a stake of 1,113 shares — an estimated $52K sold.

Strategic Capital Alternatives first reported a position in IHE in Q3 2014 and held it in 1 quarter. The position peaked at $52K in Q3 2014. 102 funds tracked by Wall St. Rank hold IHE as of Q4 2014.

  • Strategic Capital Alternatives reported no remaining iShares US Pharmaceuticals ETF position as of Q4 2014 after selling out during the quarter.
  • Strategic Capital Alternatives sold 1,113 iShares US Pharmaceuticals ETF shares in Q4 2014, an estimated $52K.
  • Strategic Capital Alternatives first reported a position in iShares US Pharmaceuticals ETF in Q3 2014 and held it in 1 quarter.
  • Strategic Capital Alternatives's iShares US Pharmaceuticals ETF position peaked at $52K in Q3 2014.
  • 102 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q4 2014.

Based on Strategic Capital Alternatives's 13F filing for Q4 2014, filed 18 Feb 2015.